The prenatal testing services market is projected to reach US$1,510.31 million by 2031 from US$571.18 million in 2024. The market is projected to register a CAGR of 15.2% from 2025 to 2031. Major factors driving market growth include the increasing demand for NIP testing, surging prevalence of genetic disorders and congenital anomalies, and rising awareness and acceptance of early genetic screening. They are propelling the acceptance of prenatal testing services. Furthermore, integration of whole-genome and multi-omic prenatal tests is expected to drive market growth during the forecast period. However, high cost of advanced tests, lack of data privacy and security, ethical, legal, and cultural concerns are among the market deterrents.

In the US, NIPT is now widely offered and used in clinical practice. Clinical guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) endorse NIPT as a first-line screening option, regardless of maternal age or risk status. Studies show that after the introduction of NIPT, the rates of invasive diagnostic procedures (such as amniocentesis and CVS) dropped significantly in one analysis, with invasive testing declining by nearly 40% between 2012 and 2015. Research suggests that NIPT has high sensitivity and specificity for common trisomies, resulting in fewer false positives and improved risk stratification. However, genetic counselors and healthcare providers continue to face challenges. The increased use of NIPT brings workload pressures, particularly in ensuring informed consent and post-test counseling. Meanwhile, population-based studies indicate that offering NIPT broadly could reduce the number of invasive procedures and associated pregnancy risks.

The comparative company analysis evaluates and categorizes the prenatal testing services market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report thoroughly examines the recent significant developments and innovations by leading vendors in the global prenatal testing services market. The key market players include Myriad Genetics Inc; Illumina Inc; Thermo Fisher Scientific Inc.; Laboratory Corp of America Holdings; and Fulgent Genetics, Inc.

In terms of diagnostic type, the prenatal testing services market is segmented into noninvasive, invasive. The noninvasive segment held a larger market share in 2024, owing to noninvasive prenatal tests provide a safe and early method for detecting chromosomal abnormalities by analyzing a simple blood sample from the mother. Due to their high precision and minimal risk, these tests are being rapidly adopted, which is leading the prenatal testing services market.

Based on disease, the prenatal testing services market is categorized into aneuploidy, microdeletions, structural chromosomal abnormalities, and others. The aneuploidy segment accounted for the largest share of the Prenatal testing services market in 2024. The aneuploidy prenatal testing market is expanding due to rising maternal age, increased adoption of non-invasive prenatal testing, technological advancements, and growing awareness of genetic disorders, while regulatory and cost challenges persist.

Based on end-user, the prenatal testing services market is segmented into hospitals, diagnostic laboratories, specialty clinics, other end users. The hospitals segment held a larger market share in 2024, owing to the integration of diagnostic services, rising maternal healthcare awareness, the adoption of advanced testing technologies, and an increasing demand for early genetic screening.

Companies operating in the prenatal testing services market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies enable market players to expand their businesses, enhance their geographic presence, and contribute to overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. The following are a few significant developments by key players in the Prenatal testing services market.

In May 2025, Roche announced a collaboration with Broad Clinical Labs to accelerate the adoption of SBX sequencing technology for critically ill newborns, with a focus on integrating whole-genome sequencing into routine clinical practice.

In April 2025, UnitedHealthcare eliminated prior authorization requirements for non-invasive prenatal testing across multiple plans, including commercial and community plans. This policy change affects cell-free fetal DNA testing procedures and aims to simplify access to healthcare for members and providers.